Deb Geraghty, PhD

Dr. Geraghty joined Anokion in 2018 as Chief Business Officer and was most recently Chief Operating Officer of the company. Dr. Geraghty brings more than 20 years of extensive experience in the life sciences industry across corporate and portfolio strategy, commercial, and finance. Prior to Anokion, Dr. Geraghty was senior vice president of corporate strategy at Dimension Therapeutics, where she had a leading role in the company’s private and initial public offering financing execution, was responsible for driving gene therapy portfolio growth, and helped lead the acquisition of the company by Ultragenyx Pharmaceutical Inc. Previous to Dimension, Dr. Geraghty was a founder and vice president, project and portfolio development at Cydan Development, an orphan drug accelerator that raised $26 million to identify and de-risk assets with therapeutic and commercial potential. Earlier in her biotech career, Dr. Geraghty served as head of portfolio advancement at Aileron Therapeutics and as director of new product marketing at Infinity Pharmaceuticals. Dr. Geraghty was a founder of Back Bay Strategies and held multiple positions at Kendall Strategies, Feinstein Kean Healthcare, and Genzyme Corp.
Dr. Geraghty also serves on the Board of Directors of ReAlta Life Sciences, Inc., where she chairs the audit committee, and the Medical University of South Carolina (MUSC) Foundation for Research Development (FRD), the university’s technology transfer office since 1998. She earned a B.S. in Biology at Union College, an M.B.A. from the Carroll School at Boston College, and a Ph.D in Molecular Biology at the University of Vermont.